Foghorn Therapeutics FHTX
NASDAQ FHTX
$2.02 -0.90 (-30.82%)
At close: Oct 2, 2026 · 4:00 PM EDT

Foghorn Therapeutics (FHTX) Gains from Sales and Divestitures (2022)

Updated

Foghorn Therapeutics (FHTX) posted Gains from Sales and Divestitures of -$31,000 for FY2025.

Analysis

Foghorn Therapeutics (FHTX) Gains from Sales and Divestitures (2022) Analysis & Trends

Since FY2019, Foghorn Therapeutics has reported Gains from Sales and Divestitures for 5 years.

  • The FY2025 figure stands as the lowest annual Gains from Sales and Divestitures in data going back to FY2019.
  • Business Quant data shows FHTX's Gains from Sales and Divestitures at -$3,000 in FY2023 and -$6,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Foghorn Therapeutics 118.60 Mn -207.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -6,000.00
API Access

Foghorn Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=FHTX&period=max&api_key=YOUR_API_KEY